16 Oct 2025 by admin in UncategorizedComments NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
16 Oct 2025 by admin in UncategorizedComments Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment- Refractory Rheumatoid Arthritis (RA)
08 Oct 2025 by admin in UncategorizedComments Zenas BioPharmand InoCare Pharma Anounce License Agrement Granting Zenas Rights for Thre Autoimune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
07 Oct 2025 by admin in UncategorizedComments Adicet Bio, Inc. Announces $80 Million Registered Direct Offering
22 Sep 2025 by admin in UncategorizedComments Avenzo Therapeutics Announces $60 Million Series B Financing
10 Sep 2025 by admin in UncategorizedComments Design Therapeutics Appoints Justin Gover to Board of Directors
02 Sep 2025 by admin in UncategorizedComments Zenas BioPharmand Royalty Pharma Enter into Obexelimab Funding Agrement for up to $30 Milion $300 Million
02 Sep 2025 by admin in UncategorizedComments Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate
21 Aug 2025 by admin in UncategorizedComments Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform
